Organization | Friedreich's Ataxia Research Alliance (FARA)

Friedreich's Ataxia Research Alliance (FARA) Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3

Founded: Downingtown PA United States (1998)

Organization Overview

First Clinical Trial

2009

NCT00803868

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2016

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 3 Trials (2)

interferon gamma-1b (actimmune) (4 trials)

varenicline (chantix) (1 trial)

Drugs in Phase 2 Trials (4)

epoetin (Epogen) (1 trial)

omaveloxolone (SKYCLARYS) (1 trial)

resveratrol (1 trial)

vatiquinone (1 trial)

Drugs in Phase 1 Trials (2)

methylprednisolone (medrol) (1 trial)

rosuvastatin (crestor) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Ataxia (Phase 3)

Cerebellar Ataxia (Phase 3)

Friedreich Ataxia (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 11
# of Trial APIs: 8